WO2022139558A1 - Composition for protecting the skin against harmful substance, light and stress - Google Patents

Composition for protecting the skin against harmful substance, light and stress Download PDF

Info

Publication number
WO2022139558A1
WO2022139558A1 PCT/KR2021/019872 KR2021019872W WO2022139558A1 WO 2022139558 A1 WO2022139558 A1 WO 2022139558A1 KR 2021019872 W KR2021019872 W KR 2021019872W WO 2022139558 A1 WO2022139558 A1 WO 2022139558A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
weight
parts
harmful substances
skin
Prior art date
Application number
PCT/KR2021/019872
Other languages
French (fr)
Inventor
Kwang Nyeon Kim
Yulia MIROMOVA
Aleksei PROKOPOV
Original Assignee
Zoe Bio Inc.
Incospharm Corporation
Medical Bioengineering Systems, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoe Bio Inc., Incospharm Corporation, Medical Bioengineering Systems, Ltd. filed Critical Zoe Bio Inc.
Priority to EP21911623.3A priority Critical patent/EP4103147A4/en
Publication of WO2022139558A1 publication Critical patent/WO2022139558A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a composition for protecting the skin against stress caused by external environments such as harmful substances and light, and the composition can protect the skin by inhibiting the abnormal response of cells by external stress stimuli such as harmful substances and light, without any cytotoxicity, so it can be usefully applied to various fields such as pharmaceuticals and cosmetics.

Description

COMPOSITION FOR PROTECTING THE SKIN AGAINST HARMFUL SUBSTANCE, LIGHT AND STRESS
The present invention relates to a composition for protecting the skin against stress caused by external environments such as harmful substances and light.
Human skin is largely divided into epidermis, dermis, and hypodermis, and the epidermis is subdivided into stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum and stratum basale. The stratum corneum, which is the outermost layer of the skin, consists of a mass of dead keratinocytes. It is primarily comprised of keratinocytes composed of protein, and the space between keratinocytes consists of lipids, such as ceramide, cholesterol, and free fatty acids. These lipid layers prevent evaporation of moisture from the body and has both of a health function to protect the body against external invasion and an aesthetic function to make the skin look shiny and smooth.
The skin is directly exposed to the external environment, and is prone to skin irritation and inflammatory reactions such as erythema, edema, and itching by harmful substances existing in the external environment. Contact with harmful substances induces stimulation and inflammatory response due to toxins, and the resulting substances can cause pigmentation of the skin, deterioration of skin elasticity, and promotion of damage to the skin barrier.
It is widely known that ultraviolet rays can accelerate skin damage and aging. In particular, when the skin is excessively exposed to ultraviolet rays, free radicals accumulate to generate active oxygen. It causes oxidative stress and destroys the antioxidant system, causing damage to the skin.
In addition, blue light emitted by displays of smart devices such as TV and computer and LED lightening device is a blue-based light with wavelength between 380 and 500 nanometers(nm), which has the shortest and strongest wavelength among visible light. There are studies that exposing the skin to blue light causes pigmentation (Luc Duteil et al. Pigment Cell Melanoma Res 2014;27:822-6).
Physical stimulation from the external environment may cause cancer due to DNA damage in cells as well as skin or may cause damage to the central and peripheral nervous system, destruction of the immune system, disorders of the reproductive system, inflammatory diseases, chronic allergies, and the like.
Therefore, there is a need for research on a composition that is safe and has no side effects while protecting the skin from external stress such as harmful substances and ultraviolet rays.
It is an object of the present invention to provide a composition for protecting the skin against stress caused by external environments such as harmful substances and light.
In order to solve the above problems, the present invention provides a composition for protecting the skin against harmful substances and light, the composition comprising:
peptides, and amino acids,
wherein the peptides comprise nicotinoyl tripeptide, pentapeptide, nicotinoyl hexapeptide, sh-octapeptide, tetracarboxymethyl hexanoyl dipeptide, hexacarboxymethyl dipeptide and biotinoyl hexapeptide-2 amide, and
the amino acids comprise arginine, asparagine, aspartic acid, glycine, histidine, hydroxyproline, isoleucine, leucine, methionine, phenylalanine, proline, serine and valine.
According to one embodiment, the composition according to the present invention may further comprise hyaluronic acid, wherein the hyaluronic acid may have a molecular mass of 500KDa to 2MDa.
According to one embodiment, the harmful substances may comprise one or more selected from the group consisting of yellow dust, fine dust, cigarette smoke, vehicle exhaust gases, heavy metals and air pollutants.
According to one embodiment, the composition may inhibit skin cell death due to stress caused by harmful substances and light.
In addition, the composition may have antioxidant activity.
In addition, the composition may inhibit the formation of cyclobutane pyrimidine dimers (CPDs).
In addition, the composition may adsorb or discharge harmful substances.
In addition, the composition may be used for improving wrinkles or enhancing elasticity.
According to one embodiment, the peptides may comprise, based on 100 parts by weight of sh-octapeptide,
1 to 50 parts by weight of nicotinoyl tripeptide;
10 to 150 parts by weight of pentapeptide;
0.05 to 10 parts by weight of nicotinoyl hexapeptide;
5 to 70 parts by weight of tetracarboxymethyl hexanoyldipeptide;
15 to 80 parts by weight of hexacarboxymethyl dipeptide; and
5 to 70 parts by weight of biotinoyl hexapeptide-2 amide, and
the amino acids may comprise, based on 100 parts by weight of valine,
80 to 180 parts by weight of arginine;
10 to 60 parts by weight of asparagine;
20 to 80 parts by weight of aspartic acid;
30 to 100 parts by weight of glycine;
50 to 150 parts by weight of histidine;
5 to 40 parts by weight of hydroxyproline;
40 to 120 parts by weight of isoleucine;
50 to 150 parts by weight of leucine;
5 to 40 parts by weight of methionine;
40 to 120 parts by weight of phenylalanine;
10 to 50 parts by weight of proline; and
20 to 80 parts by weight of serine.
According to one embodiment, the composition may further comprise 1 to 5% by weight of hyaluronic acid based on the total weight of the composition.
According to other aspect of the present invention, there is provided a cosmetic composition for improving skin darkening, wrinkles, or elasticity reduction caused by harmful substances and light, comprising the composition as described above.
According to one embodiment, the cosmetic composition may comprise non-crosslinked hyaluronic acid.
In addition, according to another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating diseases caused by harmful substances and light, comprising the composition as described above. The disease may be selected from the group consisting of cancer, atopic dermatitis, contact dermatitis, seborrheic dermatitis, erythema, sunburn, photosensitivity, acne, dry skin, psoriasis, lethality, immunotoxicity, peripheral nerve injury, central nerve injury, injury to endocrine glands, reproductive system disorders, developmental disorders in infants and young children, anemia, bronchitis, pulmonary emphysema, decreased lung function, asthma, arrhythmias, heart attack, angina pectoris, and myocardial infarction.
According to one embodiment, the pharmaceutical composition according to the present invention may be in the form of a filler injection.
According to one embodiment, the pharmaceutical composition may comprise crosslinked hyaluronic acid.
The specific details of other embodiments according to the present invention are included in the detailed description below.
The present invention protects the skin by inhibiting the abnormal response of cells by external stress stimuli such as harmful substances and light, without any cytotoxicity, so it can be usefully applied to various fields such as pharmaceuticals and cosmetics.
Fig. 1 is a graph showing the cell viability against blue light.
Fig. 2 is an optical micrograph of observing changes in skin tissue against ultraviolet rays.
Figs. 3 and 4 are graphs and micrographs showing formation of cyclobutene pyrimidine dimers (CPDs), respectively.
Fig. 5 is a graph showing the cell viability against harmful substances.
Fig. 6 is a graph showing the cell viability against harmful substances and ultraviolet rays.
Fig. 7 is a graph showing free radical scavenging ability against harmful substances and ultraviolet rays.
Figs. 8 to 10 are photographs and graphs confirming the wrinkle improvement effect according to injection of the composition of the present composition.
Since various modifications and variations can be made in the present invention, particular embodiments are illustrated in the drawings and will be described in detail in the detailed description. It should be understood, however, that the invention is not intended to be limited to the particular embodiments, but includes all modifications, equivalents, and alternatives falling within the spirit and scope of the invention. In the following description of the present invention, detailed description of known skill be omitted if it is determined that it may obscure the gist of the present invention.
Unless otherwise specified in the present specification, the expression "between" is used as an expression including the corresponding numerical value. Specifically, for example, the expression "1 to 2" is meant to include all numbers between 1 and 2 as well as 1 and 2.
Hereinafter, the composition for protecting the skin against harmful substances and light according to an embodiment of the present invention will be described in more detail.
As used herein, the term "skin protection" means to help prevent, improve, or treat skin damage against severe conditions that may be exposed from the external environment. The severe conditions include, in particular, harmful substances or light.
For example, the harmful substances may comprise one or more selected from the group consisting of yellow dust, fine dust, cigarette smoke, vehicle exhaust gases, heavy metals and air pollutants.
In addition, the term "light" as used herein means ultraviolet light, blue light, or a combination thereof, unless otherwise specified.
The air pollutants may include substances and compounds designated in Article 4 of the Clean Air Conservation Act (revision in 2019). Specifically, air pollutants may include one or more selected from the group consisting of cadmium and its compounds, hydrogen cyanide, lead and its compounds, polychlorinated biphenyls, chromium and its compounds, arsenic and its compounds, mercury and its compounds, propylene oxide, chlorine and its compounds, fluorine compounds, asbestos, nickel and its compounds, vinyl chloride, dioxin, phenol and its compounds, beryllium and its compounds, benzene, carbon tetrachloride, methyl disulfide, aniline, chloroform, formaldehyde, acetaldehyde, benzidine, 1,3-butadiene, polycyclic aromatic hydrocarbons, ethylene oxide, dichloromethane, styrene, tetrachloroethylene, 1,2-dichloroethane, ethylbenzene, trichloroethylene, acrylonitrile and hydrazine.
The present invention provides a composition for protecting skin against stress caused by harmful substances and light, comprising peptides.
Specifically, the present invention comprises nicotinoyl tripeptide, pentapeptide-37, nicotinoyl hexapeptide, sh-octapeptide, tetracarboxymethyl hexanoyl dipeptide, hexacarboxymethyl dipeptide and biotinoyl hexapeptide-2 amide.
Nicotinoyl tripeptide is the product obtained by the reaction vitamin B3 (nicotinic acid, niacin) and tripeptide, a skin activating peptide, and helps to reduce skin hypersensitivity.
Pentapeptide helps skin whitening and moisturizing.
Nicotinoyl hexapeptide is the product obtained by the reaction vitamin B3 and hexapeptide that lowers the function of PAR2 (signal transduction receptor) causing exogenous aging, and helps to prevent oxidation and protect skin.
Sh-octapeptide is a single-chain recombinant human peptide containing 8 amino acids consisting of glycine, histidine, leucine, lysine, phenylalanine, and tyrosine, and prevents oxidation damage to the skin.
Tetracarboxymethyl hexanoyl dipeptide and hexacarboxymethyl dipeptide are used as a skin conditioning agent.
Biotinoyl hexapeptide-2 amide is the product obtained by the reaction of hexapeptide-2 and biotin, wherein the C-terminus of the peptide is an amide, and is used as a skin conditioning agent.
According to one embodiment, the peptides may comprise, based on 100 parts by weight of sh-octapeptide,
1 to 50 parts by weight, such as 5 to 30 parts by weight, such as 10 to 30 parts by weight of nicotinoyl tripeptide;
10 to 150 parts by weight, such as 30 to 100 parts by weight, such as 50 to 70 parts by weight of pentapeptide;
0.05 to 10 parts by weight, such as 0.1 to 5 parts by weight, such as 0.5 to 4 parts by weight of nicotinoyl hexapeptide;
5 to 70 parts by weight, such as 10 to 50 parts by weight, such as 20 to 40 parts by weight of tetracarboxymethyl hexanoyldipeptide;
15 to 80 parts by weight, such as 30 to 60 parts by weight, such as 40 to 50 parts by weight of hexacarboxymethyl dipeptide; and
5 to 70 parts by weight, such as 10 to 50 parts by weight, such as 20 to 40 parts by weight of biotinoyl hexapeptide-2 amide.
According to one embodiment, the present invention may further comprise amino acids, in particular the amino acids may further comprise one or more amino acids selected from the group consisting of arginine, asparagine, aspartic acid, glycine, histidine, hydroxyproline, isoleucine, leucine, methionine, phenylalanine, proline, serine and valine, for example.
Specifically, the amino acids may comprise, based on 100 parts by weight of valine,
80 to 180 parts by weight, such as 50 to 250 parts by weight, such as 70 to 150 parts, such as 90 to 130 parts by weight by weight of arginine;
10 to 60 parts by weight, such as 20 to 50 parts by weight, such as 25 to 40 parts by weight of asparagine;
20 to 80 parts by weight, such as 30 to 70 parts by weight, such as 35 to 50 parts by weight of aspartic acid;
30 to 100 parts by weight, such as 40 to 80 parts by weight, such as 40 to 60 parts by weight of glycine;
50 to 150 parts by weight, such as 60 to 120 parts by weight, such as 70 to 100 parts by weight of histidine;
5 to 40 parts by weight, such as 10 to 30 parts by weight, such as 10 to 20 parts by weight of hydroxyproline;
40 to 120 parts by weight, such as 50 to 100 parts by weight, such as 60 to 80 parts by weight of isoleucine;
50 to 150 parts by weight, such as 60 to 120 parts by weight, such as 70 to 100 parts by weight of leucine;
5 to 40 parts by weight, such as 10 to 30 parts by weight, such as 10 to 20 parts by weight of methionine;
40 to 120 parts by weight, such as 50 to 100 parts by weight, such as 60 to 80 parts by weight of phenylalanine;
10 to 50 parts by weight, such as 20 to 40 parts by weight, such as 20 to 30 parts by weight of proline; and
20 to 80 parts by weight, such as 30 to 60 parts by weight, such as 35 to 50 parts by weight of serine.
The composition according to the present invention can protect skin cells by adsorbing or discharging harmful substances.
In addition, it can inhibit skin damage caused by ultraviolet rays. The skin can have UV-induced DNA damage, which causes the formation of cyclobutane pyrimidine dimers (CPD). In CPDs, double bonds in the hexagonal ring structures of adjacent pyrimidine bases are transformed by exposure to short-wavelength (about 254 nm) ultraviolet light to form a new tetragonal bond, which induces abnormal binding to cause structural defects in DNA. The composition according to the present invention can inhibit the formation of CDPs, thereby inhibiting apoptosis of skin cells due to ultraviolet rays.
In addition, it is possible to improve antioxidant activity, prevent and alleviate skin cell damage due to stress caused by harmful substances and light, thereby improving skin darkening, wrinkles, or decreased skin elasticity.
According to one embodiment, the composition of the present invention may be prepared in any formulation that can be applied dermatologically, such as a conventional cosmetic composition, a pharmaceutical composition for external application on the skin, and the like. The dermatologically applicable composition refers to a composition that can have a relatively non-toxic and harmless effective action to the subject and may comprise an external preparation that can be applied to the skin, in which the composition does not impair the activity and properties of the active ingredient without causing side effects resulting from the composition and does not reduce the efficacy of the active ingredient and cause serious irritation to the subject.
In addition, the composition for external application for skin of the present invention can be formulated in any form that can be accepted in the art, which is exemplified by solution, suspension, fluid, emulsion, paste, gel, pack, cream, lotion, powder, soap, surfactant-containing cleansing agent, oil, powder foundation, emulsion foundation, wax foundation, spray, and hair cosmetics, but is not limited thereto.
Specifically, the cosmetic composition may be formulated into skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, foundation, essence, nourishing essence, pack, soap, hair shampoo, foot shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser, etc., and for example, it may be prepared in the formulations of a cosmetic filler.
The cosmetic filler may be applied by a method of application to the skin surface. It may comprise fragrance, xanthan gum, wax, butter, oil, surfactant, moisturizer, alcohol, and it may be included without particular limitation as long as it is a component of the cosmetic composition that is commonly used. In addition, when the cosmetic filler composition contains hyaluronic acid, the hyaluronic acid may comprise a non-crosslinked structure.
In addition, according to another embodiment of the present invention, there is provided a pharmaceutical composition for preventing or treating diseases caused by harmful substances and light. Specifically, the disease may be selected from the group consisting of cancer, atopic dermatitis, contact dermatitis, seborrheic dermatitis, erythema, sunburn, photosensitivity, acne, dry skin, psoriasis, lethality, immunotoxicity, peripheral nerve injury, central nerve injury, injury to endocrine glands, reproductive system disorders, developmental disorders in infants and young children, anemia, bronchitis, pulmonary emphysema, decreased lung function, asthma, arrhythmias, heart attack, angina pectoris, and myocardial infarction.
According to one embodiment, the pharmaceutical composition according to the present invention may contain a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier includes binders, glidants, disintegrants, excipients, lubricants, solubilizers, dispersants, stabilizers, suspending agents, colorants, fragrances, buffers, preservatives, softening agent, painless agents, solubilizers, isotonic agents, or a combination thereof. The dosage form of the pharmaceutical composition of the present invention may be prepared in various ways by mixing with a pharmaceutically acceptable carrier as described above. The pharmaceutical composition according to the present invention may be formulated into a medical supplement, solution, suspension, ointment, tablet, capsule, etc., but the present invention is not limited thereto.
The medical supplement may include medical fillers, wound dressings, bone grafts, soft tissue supplements, dental materials, etc., which can be applied to artificial tissues, artificial organs, cell culture scaffolds, drug delivery agents, biosensors for transplantation, etc.
According to one embodiment, the composition according to the present invention may be formulated into a filler injection, which may comprise one or more carriers selected from the group consisting of alginic acid, carboxymethyl cellulose, chitosan, dextran, collagen, gelatin, pectin, agar, amylose, cyclodextrin and elastin. In addition, when the injection composition for a filler contains hyaluronic acid, the hyaluronic acid may comprise a crosslinked structure.
In addition, for example, a biodegradable polymer scaffold may include hyaluronic acid, polyglycolic acid (PGA), polylactic acid (PLA), polylactic acid-glycolic acid copolymer (PLGA), poly-ε-caprolactone (PCL), polyamino acid, polyanhydride, polyorthoester, or a copolymer thereof.
According to one embodiment, the composition according to the present invention comprises hyaluronic acid. Hyaluronic acid may include a salt thereof or crosslinked hyaluronic acid, for example, sodium hyaluronate. In addition, for example, the hyaluronic acid may have a molecular mass of 500 KDa to 2 MDa, for example, 1 to 2 MDa, for example, 1 to 1.5 MDa. The content of hyaluronic acid in the present invention may be 1 to 5% by weight, for example, 1 to 3% by weight based on the total weight of the composition.
According to one embodiment, the biodegradable polymer scaffold may have pores formed therein, the pores being formed by salts, effervescent salts, carbohydrates, hydrocarbon waxes, and the like.
In addition, the filler injection according to the present invention may comprise a local anesthetic, an antihistamine, a vitamin, and the like.
The local anesthetic may include, for example, lidocaine, etidocaine, bupivacaine, tetracaine, mepivacaine, procaine, prilocaine, ropivacaine, etc., but is not particularly limited as long as it is a local anesthetic for injection.
The antihistamine may include, for example, Plokon (piprinhydrinate), chlorpheniramine, diphenylpyraline, diphenhydramine, cetirizine, etc., but is not particularly limited as long as it is antihistamines for injection.
Hereinafter, embodiments of the present invention will be described in detail so that those of ordinary skill in the art can easily carry out the present invention. However, the present invention may be embodied in various different forms and is not limited to the embodiments described herein.
Examples
A composition for skin protection was prepared with the composition shown in Table 1.
Ingredients Composition
% ppm
Peptides Nicotinoyl tripeptide-1 0.00012 1.2
Pentapeptide-37 0.00040 4.0
Nicotinoyl hexapeptide-44 0.00001 0.1
sh-Octapeptide-4 0.00060 6.0
Tetracarboxymethyl Hexanoyl Dipeptide-12 0.00020 2.0
Hexacarboxymethyldipepdite-12 0.00029 2.9
Biotinoyl hexapeptide-2 amide 0.00020 2.0
Amino acids Arginine 0.00062 6.2
Asparagine 0.00016 1.6
Aspartic acid 0.00020 2.0
Glycine 0.00028 2.8
Histidine 0.00040 4.0
Hydroxyproline 0.00008 0.8
Isoleucine 0.00036 3.6
Leucine 0.00040 4.0
Methinonine 0.00008 0.8
Phenylalanine 0.00034 3.4
Proline 0.00012 1.2
Serine 0.00022 2.2
Valine 0.00050 5.0
Hyaluronic acid, as sodium hyaluronate 1.50000 15000
Water To 100
Experimental Example 1: Cell protection against blue light
To confirm the cytoprotective effect of the composition according to the present invention against blue light, the MTS ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay, a cell viability assay, was performed using human fibroblasts (NHDFs).
Human fibroblast (Normal Human foreskin-derived Dermal Fibroblasts, NHDFs; ATCC, CRL-2522) cells were placed in a 24-well plate at a concentration of 3×104 cells/well and cultured in DMEM containing 10% fetal bovine serum plus 100 U/mL of penicillin/streptomycin at 5% CO2 and 37 ℃ for 24 hours. The composition of Example was prepared with a concentration of 0 to 1.0%, and the cultured cells were treated with the composition for 24 hours, and then subjected to irradiation with blue light (453 nm, 40 J/cm2) for 6 hours to measure cell viability. For measurement, after removing the culture medium, the cells were treated with the MTS solution (0.33 mg/mL MTS) for 1 to 4 hours, and absorbance was measured at 490 nm with a spectrophotometer (Epoch 2, BioTek).
The MTS assay results of the effect of protecting human fibroblasts against blue light are shown in Fig. 1. As a result, in terms of cell viability against blue light irradiation, the group treated with the composition according to the present invention exhibited 1 to 11% higher cell viability compared to the blue light-irradiated group not treated with the composition.
Experimental Example 2: Prevention of skin damage caused by ultraviolet rays (ex vivo)
To confirm the prevention effect on skin damage of the composition of Example (product S), the skin biopsies treated with the composition of Example were irradiated with UVA/UVB to measure the formation of skin explants (H/E Staining) and the amount of cyclobutane pyrimidine dimers (CPDs). UV irradiation causes DNA damage, which is caused by the formation of CPDs.
Full-thickness human skin tissues, an ex vivo model, had received ethical approval with the informed consent, and the details are shown in Table 2. The collected skin tissues were cultured for 24 hours under the conditions of 5% CO2 and 37 ℃, and then the test was performed.
The skin explants were cultured in a 12-well plate for 24 hours, then the sample (the composition of Example) was prepared with a concentration of 30% and the cultured cells were treated with the sample for 24 hours and irradiated with ultraviolet rays (UVA/UVB) for 5 hours. The shape of the skin tissues (6 μm thick section) was observed with an optical microscope (DM2000, lens20X) by Hematoxylin/eosin staining (H/E staining) (Fig. 2).
Then, the specimen tissue was treated under the same CPDs test conditions as in the above method, and then irradiated with ultraviolet rays (UVA/UVB) according to the time (30 min, 1 hr 30 min, 5 hrs).
For measurement, the abundance of CPDs was measured using immunohistochemistry (IHC) with paraffin-embedded tissue section (Fig. 3) and the specimen tissues were observed with an optical microscope (Fig. 4). The dose of UV A radiation was 50 J/cm2, and the dose of UV B radiation was 500 mJ/cm2.
In Fig. 2, the thickness of the epidermal layer and the density of the dermal layer were evaluated as an indicator of photoaging by UV rays. Through observation of the skin tissues, it was confirmed that in the UV-irradiated group not treated with the composition of Example, the epidermal layer was thickened, and the density of the dermal layer was decreased. On the other hand, it was confirmed that in the group treated with the composition of Example (product S), the epidermal layer had thin thickness, and the density of the dermal layer was increased.
In Fig. 3, the abundance of CPDs showed an average decrease of 3 to 7% in the UV-irradiated group treated with the composition of Example, compared to the UV-irradiated group not treated with the composition of Example.
Through observation of the CPDs generation in the skin tissues in Fig. 4, the generation of CPDs was obviously seen in the UV-irradiated group not treated with the composition of Example. On the other hand, in the UV-irradiated group treated with the composition of Example, the generation of CPDS showed a tendency to decrease, compared to the UV-irradiated group not treated with the composition of Example.
Experimental Example 3: Cell protection against air pollutants (in vivo)
To confirm the cytoprotective effect of the composition according to the present invention against air pollutants, human fibroblasts (NHDFs) were treated with urban dust as air pollutants and the composition of Example. Evaluation was carried out using the MTS ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay, a cell viability assay.
As urban dust (SRM1649b, US National Institute of Standards and Technology (NIST)), atmospheric particles collected in Washington, D.C. between 1976 and 1977 were used. The urban dust contains various compounds, such as PAHs (Polycyclic aromatic hydrocarbons), nitrosubstituted polycyclic aromatic hydrocarbons, PCB (polychlorinated biphenyl) congeners, chlorinated pesticides, decabromodiphenyl ether (decaBDE), dibenzo-p-dioxin and dibenzofuran congeners. The particle size is about 10 μm.
Human fibroblast (normal human foreskin-derived dermal fibroblasts, NHDFs; ATCC, CRL-2522) cells were placed in a 24-well plate at a concentration of 3×104 cells/well and cultured in DMEM containing 10% fetal bovine serum plus 100 U/mL of penicillin/streptomycin at 5% CO2 and 37 ℃ for 24 hours. The composition of Example was prepared with a concentration of 0 to 10%, and the cultured cells were treated with the composition for 6 hours. Then, the cells were treated with 200 μg/ml of urban dust for 18 hours to measure cell viability. For measurement, after removing the culture medium, the cells were treated with MTS solution (0.33 mg/mL MTS) for 1 to 4 hours, and absorbance was measured at 490 nm with a spectrophotometer (Epoch 2, BioTek).
The MTS assay results of the effect of protecting human fibroblasts from urban dust are shown in Fig. 5. As a result, in terms of cell viability against urban dust, the group treated with the composition according to the present invention exhibited 8 to 13% higher cell viability compared to the urban dust group not treated with the composition.
Therefore, it was confirmed that the present invention exhibits an antipollution effect on the skin from air pollutants.
Experimental Example 4: Cell protection against air pollutants and UV rays (in vivo)
To confirm the cytoprotective effect of the composition according to the present invention against air pollutants and ultraviolet rays, human fibroblasts (NHDFs) were treated with urban dust as air pollutants and irradiated with UV A rays to evaluate the cytoprotective effect on the peptide composition. Evaluation was carried out using the MTS ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay, a cell viability assay.
Human fibroblast (normal human foreskin-derived dermal fibroblasts, NHDFs; ATCC, CRL-2522) cells were placed in a 24-well plate at a concentration of 3×104 cells/well and cultured in DMEM containing 10% fetal bovine serum plus 100 U/mL of penicillin/streptomycin at 5% CO2 and 37 ℃ for 24 hours. The sample (the composition of Example) was prepared with a concentration of 1%, and the cultured cells were treated with the sample for 24 hours and then treated with 80 μg/ml of urban dust for 24 hours and irradiated with UV A rays with 10 J/cm2 to measure cell viability. For measurement, after removing the culture medium, the cells were treated with MTS solution (0.33 mg/mL MTS) for 1 to 4 hours, and absorbance was measured at 490 nm with a spectrophotometer (Epoch 2, BioTek).
The MTS assay results of the effect of protecting human fibroblasts from urban dust (UbD) as air pollutants and UV A irradiation are shown in Fig. 6. As a result, the group treated with the composition of Example showed the cell viability of about 16% or more higher than that of the urban dust + UVA group not treated with the composition.
Therefore, it was confirmed that the present invention exhibits a cytoprotective effect when simultaneously treated with air pollutants and UV irradiation.
Experimental Example 5: Cellular oxidative stress by air pollutants and UV rays
To confirm the protective effect of the composition according to the present invention against cellular oxidative stress, the production of free radicals (ROS) was measured.
H2DCFDA (2',7'-dichlorodihydrofluorescein diacetate) assay was used to measure the production of intracellular free radical (ROS). H2DCFDA (2',7'-dichlorodihydrofluorescein diacetate) assay is based on the principle of conversion of H2DCFDA to its fluorescent product DCF (2',7'-dichlorodihydrofluorescein).
Human fibroblast (normal human foreskin-derived dermal fibroblasts, NHDFs; ATCC, CRL-2522) cells were placed in a 24-well plate at a concentration of 3×104 cells/well and cultured in DMEM containing 10% fetal bovine serum plus 100 U/mL of penicillin/streptomycin at 5% CO2 and 37 ℃ for 24 hours. The sample (the composition of Example) was prepared with a concentration of 1%, and the cultured cells were treated with the sample for 24 hours and then 10 μM of DCFDA (Fisher Scientific, D399) was added thereto. Then, the cells were cultured for 30 minutes. DCFDA was used with dilution in HBSS solution. After removing the DCFDA solution, the cells were washed with the HBSS solution 2 times and treated with 80 μg/ml of urban dust for 24 hours and UVA irradiation with 10 J/cm2. Intracellular fluorescence intensity was measured using a fluorophotometer (Victor3,1420 Multilabel counter, Perkin Elmer) with excitation of 485 nm and emission of 520 nm. The results are shown in Fig. 7. It was confirmed that the free radical scavenging ability was improved by about 73% or more in the sample-treated group compared to the sample-untreated group.
Experimental Example 6: Wrinkle improvement effect
To confirm the wrinkle improvement effect of the composition according to the present invention, an injection containing the composition of Example as shown in Table 1 was used.
The test was conducted for healthy women aged 35 to 55 years. 2 ml of the injection composition was injected into the skin 3 times with 2-week interval to confirm the wrinkle improvement effect. The state of the wrinkles was evaluated by photography and 3D analysis.
The results are shown in Fig. 8 to Fig. 10, comparing the photographs before and after injecting of the injection into winkled areas.
As shown in Figs. 8 to 10, when the composition according to the present invention was injected 3 times with 2-week interval, it was confirmed that the wrinkle improvement rate was improved by 10 to 20%.
As can be seen from the above results, it was confirmed that the present invention has no toxicity to skin cells and can protect skin cells from harmful substances or light in the external environment.
The above descriptions are merely illustrative of the technical idea of the present invention, and those of ordinary skill in the technical field to which the present invention pertains can make various modifications and variations without departing from the essential characteristics of the present invention. In addition, the embodiments disclosed in the present invention are not intended to limit the technical idea of the present invention, but to explain the technical idea, and the scope of the technical idea of the present invention is not limited by these embodiments. The scope of protection of the present invention should be interpreted by the appended claims, and all technical ideas within the scope equivalent thereto should be interpreted as being included in the scope of the present invention.

Claims (15)

  1. A composition for protecting the skin against harmful substances and light, the composition comprising:
    peptides, and amino acids,
    wherein the peptides comprise nicotinoyl tripeptide, pentapeptide, nicotinoyl hexapeptide, sh-octapeptide, tetracarboxymethyl hexanoyl dipeptide, hexacarboxymethyl dipeptide and biotinoyl hexapeptide-2 amide, and
    the amino acids comprise arginine, asparagine, aspartic acid, glycine, histidine, hydroxyproline, isoleucine, leucine, methionine, phenylalanine, proline, serine and valine.
  2. The composition for protecting the skin against harmful substances and light according to claim 1, wherein the composition further comprises a hyaluronic acid and wherein the hyaluronic acid has a molecular mass of 500KDa to 2MDa.
  3. The composition for protecting the skin against harmful substances and light according to claim 1, wherein the harmful substances comprise one or more selected from the group consisting of yellow dust, fine dust, cigarette smoke, vehicle exhaust gases, heavy metals and air pollutants.
  4. The composition for protecting the skin against harmful substances and light according to claim 1, wherein the composition inhibits skin cell death due to stress caused by harmful substances, light or a combination thereof.
  5. The composition for protecting the skin against harmful substances and light according to claim 1, wherein the composition has antioxidant activity.
  6. The composition for protecting the skin against harmful substances and light according to claim 1, wherein the composition inhibits the formation of cyclobutane pyrimidine dimers (CPDs).
  7. The composition for protecting the skin against harmful substances and light according to claim 1, wherein the composition adsorbs or discharges harmful substances.
  8. The composition for protecting the skin against harmful substances and light according to claim 1, wherein the composition is used for improving wrinkles or enhancing elasticity.
  9. The composition for protecting the skin against harmful substances and light according to claim 1, wherein the peptides comprise, based on 100 parts by weight of sh-octapeptide,
    1 to 50 parts by weight of nicotinoyl tripeptide;
    10 to 150 parts by weight of pentapeptide;
    0.05 to 10 parts by weight of nicotinoyl hexapeptide;
    5 to 70 parts by weight of tetracarboxymethyl hexanoyldipeptide;
    15 to 80 parts by weight of hexacarboxymethyl dipeptide; and
    5 to 70 parts by weight of biotinoyl hexapeptide-2 amide, and
    the amino acids comprise, based on 100 parts by weight of valine,
    80 to 180 parts by weight of arginine;
    10 to 60 parts by weight of asparagine;
    20 to 80 parts by weight of aspartic acid;
    30 to 100 parts by weight of glycine;
    50 to 150 parts by weight of histidine;
    5 to 40 parts by weight of hydroxyproline;
    40 to 120 parts by weight of isoleucine;
    50 to 150 parts by weight of leucine;
    5 to 40 parts by weight of methionine;
    40 to 120 parts by weight of phenylalanine;
    10 to 50 parts by weight of proline; and
    20 to 80 parts by weight of serine.
  10. The composition for protecting the skin against harmful substances and light according to claim 1, wherein the composition further comprises 1 to 5% by weight of hyaluronic acid based on the total weight of the composition.
  11. A cosmetic composition for improving skin darkening, wrinkles, or elasticity reduction caused by harmful substances and light, comprising the composition according to any one of claims 1 to 10.
  12. The cosmetic composition according to claim 11, wherein the composition comprises non-crosslinked hyaluronic acid.
  13. A pharmaceutical composition for preventing or treating diseases caused by harmful substances and light, comprising the composition according to any one of claims 1 to 10,
    wherein the disease is selected from the group consisting of cancer, atopic dermatitis, contact dermatitis, seborrheic dermatitis, erythema, sunburn, photosensitivity, acne, dry skin, psoriasis, lethality, immunotoxicity, peripheral nerve injury, central nerve injury, injury to endocrine glands, reproductive system disorders, developmental disorders in infants and young children, anemia, bronchitis, pulmonary emphysema, decreased lung function, asthma, arrhythmias, heart attack, angina pectoris, and myocardial infarction.
  14. A pharmaceutical composition according to claim 13, wherein the composition is in the form of a filler injection.
  15. A pharmaceutical composition according to claim 13, wherein the composition comprises crosslinked hyaluronic acid.
PCT/KR2021/019872 2020-12-24 2021-12-24 Composition for protecting the skin against harmful substance, light and stress WO2022139558A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21911623.3A EP4103147A4 (en) 2020-12-24 2021-12-24 Composition for protecting the skin against harmful substance, light and stress

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200183691A KR102378053B1 (en) 2020-12-24 2020-12-24 Composition for protecting the skin against harmful substance, light and stress
KR10-2020-0183691 2020-12-24

Publications (1)

Publication Number Publication Date
WO2022139558A1 true WO2022139558A1 (en) 2022-06-30

Family

ID=80935587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/019872 WO2022139558A1 (en) 2020-12-24 2021-12-24 Composition for protecting the skin against harmful substance, light and stress

Country Status (3)

Country Link
EP (1) EP4103147A4 (en)
KR (1) KR102378053B1 (en)
WO (1) WO2022139558A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023200874A1 (en) * 2022-04-13 2023-10-19 ALASTIN Skincare, Inc. Combination of octapeptide and high molecular weight hyaluronic acid for topical application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620419B1 (en) * 1998-09-15 2003-09-16 Sederma Cosmetic or dermopharmaceutical use of peptides for healing, hydrating and improving skin appearance during natural or induced ageing (heliodermia, pollution)
WO2015113307A1 (en) * 2014-01-30 2015-08-06 Dow Corning Corporation Compositions for application to the skin for reducing adhesion of pollution particles on skin and methods of preparing same
WO2019078370A1 (en) * 2017-10-20 2019-04-25 ロート製薬株式会社 Composition for ameliorating skin disorders
KR20200005499A (en) * 2018-07-06 2020-01-15 애니젠 주식회사 Cosmetic composition for eliminating or adsorbing particulate matter comprising peptide complex as effective component
KR20200078433A (en) * 2020-06-11 2020-07-01 주식회사 리턴바이오 Cosmetic composition for anti-wrinkle and whitening containing various growth factor and peptide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160128889A (en) * 2015-04-29 2016-11-08 주식회사 엘지생활건강 Soluble Microneedle comprising Vitamin or derivatives thereof
KR101684415B1 (en) * 2016-06-30 2016-12-07 주식회사 뉴앤뉴 Cosmetic composition of water-in-oil with liposome hexacarboxymethyl dipeptide-12 and menufacturing method thereof
KR101836781B1 (en) * 2017-10-20 2018-04-19 한승우 Apparatus for power train, vehicle including the same and control method for the same those
KR101989789B1 (en) * 2017-11-30 2019-06-18 (주) 에이치엔에이파마켐 Cochleates using phosphatidylserine/anionic surfactant/calcium chloride
KR102099269B1 (en) * 2020-01-22 2020-04-10 신승연 Two-part skin care formulations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620419B1 (en) * 1998-09-15 2003-09-16 Sederma Cosmetic or dermopharmaceutical use of peptides for healing, hydrating and improving skin appearance during natural or induced ageing (heliodermia, pollution)
WO2015113307A1 (en) * 2014-01-30 2015-08-06 Dow Corning Corporation Compositions for application to the skin for reducing adhesion of pollution particles on skin and methods of preparing same
WO2019078370A1 (en) * 2017-10-20 2019-04-25 ロート製薬株式会社 Composition for ameliorating skin disorders
KR20200005499A (en) * 2018-07-06 2020-01-15 애니젠 주식회사 Cosmetic composition for eliminating or adsorbing particulate matter comprising peptide complex as effective component
KR20200078433A (en) * 2020-06-11 2020-07-01 주식회사 리턴바이오 Cosmetic composition for anti-wrinkle and whitening containing various growth factor and peptide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4103147A4 *

Also Published As

Publication number Publication date
EP4103147A1 (en) 2022-12-21
EP4103147A4 (en) 2023-08-09
KR102378053B1 (en) 2022-03-25

Similar Documents

Publication Publication Date Title
ES2393927T3 (en) Topical compositions
Aoshima et al. Safety evaluation of highly purified fullerenes (HPFs): based on screening of eye and skin damage
WO2020171285A1 (en) Peptide for preventing skin damage caused by air pollutants and for anti-aging, and use thereof
WO2022139558A1 (en) Composition for protecting the skin against harmful substance, light and stress
KR20170132855A (en) Protective effect of lutein on blue light for human skin cell line
WO2018004300A1 (en) Plasma generating device, and method for treating hair loss using same
WO2021112398A1 (en) Composition comprising vitamin c
WO2017200288A1 (en) Composition for whitening skin, preventing skin aging or improving skin wrinkles, comprising natural oriental medicinal extract as active ingredient
WO2012020989A9 (en) Pharmaceutical or cosmetic composition containing nicotinic acid adenine dinucleotide phosphate or derivative thereof
JP4050173B2 (en) Cosmetic or dermatological composition comprising a combination of tetrahydrocurcuminoid and amide oil
WO2018111042A2 (en) Cosmetic composition comprising extract of medicinal herbs as active ingredient
WO2023055007A1 (en) Peptide having anti-aging activity, and use thereof
WO2013042811A1 (en) Caffeoyl alpha neoendorphin peptide derivative and use thereof as an anti-itch and anti-atopic material
RU2792212C1 (en) Composition for skin protection from exposure to harmful substances, light and stress
WO2023054817A1 (en) Peptide having anti-aging activity, and use thereof
WO2021145699A1 (en) Composition for treating skin diseases, comprising colchicine
KR101638664B1 (en) Pharmaceutical composition for preventing or treating infectious diseases of skin comprising 5-Aminolevulinic acid
JP2005290002A (en) Cosmetic use of at least one inhibitor of rhoa kinase production and/or activation, as agent for relaxing features and/or for decontracting skin
WO2022131820A1 (en) Anti-inflammatory peptide for preventing or treating atopic dermatitis
WO2019059511A2 (en) Cosmetic composition containing 3,4-dicaffeoylquinic acid for skin protection against reactive oxygen species, ultraviolet radiation, or fine dust
WO2021010596A1 (en) Cosmetic composition comprising graphene oxide as active ingredient
WO2019190290A1 (en) Composition for alleviating skin barrier dysfunction
WO2022154247A1 (en) Composition for improving dead skin cell exfoliation or skin condition
WO2024043713A1 (en) Composition comprising natural killer cell-derived exosome and biocompatible polymer as active ingredients, and use thereof
WO2024043716A1 (en) Composition comprising human cell-derived microvesicles and hyaluronic acid or collagen, and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21911623

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021911623

Country of ref document: EP

Effective date: 20220914

NENP Non-entry into the national phase

Ref country code: DE